Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07188428 · ClinicalTrials.gov registry record
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
A clinical trial of Leukemia, Chronic Myeloid, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,298
- Enrollment target
- 1
- Study location
NCT07188428 is a study of Leukemia, Chronic Myeloid that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,298 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07188428, a study of Leukemia, Chronic Myeloid, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,298 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line therapy.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,298 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2024-12-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07188428
The ClinicalTrials.gov registry entry for NCT07188428 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Chronic Myeloid appearing as the primary indexed condition, and to 0 interventions.
NCT07188428 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07188428 about?
NCT07188428 is a clinical study titled "Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment". The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line therapy.
What is the current status of trial NCT07188428?
This trial is currently completed. The enrollment target is 2,298 participants. The study started on 2024-02-27. Estimated completion is 2024-12-02.
What conditions does trial NCT07188428 study?
This clinical trial studies the following conditions: Leukemia, Chronic Myeloid.
Who is sponsoring clinical trial NCT07188428?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07188428 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Chronic Myeloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.